Related Experiment Video
Updated: Jul 14, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol
Derek E Piper1, Simon Jackson, Qiang Liu
1Department of Molecular Structure, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, USA.
Abstract:
Proprotein convertase subtilisin kexin type 9 (PCSK9) has been shown to be involved in the regulation of extracellular levels of the low-density lipoprotien receptor (LDLR). Although PCSK9 is a subtilase, it has not been shown to degrade the LDLR, and its LDLR-lowering mechanism remains uncertain. Here we report the crystal structure of human PCSK9 at 2.3 A resolution. PCSK9 has subtilisin-like pro- and catalytic domains, and the stable interaction between these domains prevents access to PCSK9's catalytic site. The C-terminal domain of PCSK9 has a novel protein fold and may mediate protein-protein interactions. The structure of PCSK9 provides insight into its biochemical characteristics and biological function.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Regulation of Nuclear Protein Sorting
Receptor-mediated Endocytosis
Cholesterol: Significance and Regulation
Considering cholesterol and...
